BioCardia and CART-Tech enter exclusive pact for Heart3D Fusion Imaging

BioCardia, Inc.

Exclusive development/commercialization agreement for Heart3D Fusion Imaging, enhancing 2D x-rays with 3D anatomical models.
BioCardia gets exclusive global rights for biotherapeutic delivery and US rights for cardiac biopsy distribution.
Management estimates $100M annual revenue potential from Heart3D if single large-market biologic becomes standard of care.
Cross-licensing: BioCardia licenses CART-Tech IP for biotherapeutic intervention; CART-Tech licenses BioCardia IP for CRT.
Heart3D initially sold as research tool for preclinical studies, later for clinical practice.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.